VEA
UBX

Virtus ETF Advisers’s Unity Biotechnology UBX Stock Holding History

Virtus ETF Advisers’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,301
Closed -$249K – 489
2020
Q1 		$249K Sell
4,301
-627
-13% -$39.5K 0.1% 251
2019
Q4 		$355K Buy
4,928
+2,034
+70% +$143K 0.06% 282
2019
Q3 		$177K Sell
2,894
-161
-5% -$11.4K 0.04% 267
2019
Q2 		$290K Buy
3,055
+1,402
+85% +$119K 0.06% 230
2019
Q1 		$134K Sell
1,653
-246
-13% -$27.9K 0.29% 98
2018
Q4 		$309K Buy
+1,899
New +$252K 0.05% 101

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtus ETF Advisers's UBX Position: Q2 2020 in Review

Virtus ETF Advisers sold out of Unity Biotechnology (UBX) in Q2 2020, closing a stake of 4,301 shares — an estimated $249K sold.

Virtus ETF Advisers first reported a position in UBX in Q4 2018 and held it in 6 quarters. The position peaked at $355K in Q4 2019. 84 funds tracked by Wall St. Rank hold UBX as of Q2 2020.

  • Virtus ETF Advisers reported no remaining Unity Biotechnology position as of Q2 2020 after selling out during the quarter.
  • Virtus ETF Advisers sold 4,301 Unity Biotechnology shares in Q2 2020, an estimated $249K.
  • Virtus ETF Advisers first reported a position in Unity Biotechnology in Q4 2018 and held it in 6 quarters.
  • Virtus ETF Advisers's Unity Biotechnology position peaked at $355K in Q4 2019.
  • 84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2020.

Based on Virtus ETF Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.